Cargando…

Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Salam, Kazi Abdus, Akimitsu, Nobuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825274/
https://www.ncbi.nlm.nih.gov/pubmed/24282816
http://dx.doi.org/10.1155/2013/467869
_version_ 1782290791324975104
author Salam, Kazi Abdus
Akimitsu, Nobuyoshi
author_facet Salam, Kazi Abdus
Akimitsu, Nobuyoshi
author_sort Salam, Kazi Abdus
collection PubMed
description Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors.
format Online
Article
Text
id pubmed-3825274
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38252742013-11-26 Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives Salam, Kazi Abdus Akimitsu, Nobuyoshi Biomed Res Int Review Article Currently, hepatitis C virus (HCV) infection is considered a serious health-care problem all over the world. A good number of direct-acting antivirals (DAAs) against HCV infection are in clinical progress including NS3-4A protease inhibitors, RNA-dependent RNA polymerase inhibitors, and NS5A inhibitors as well as host targeted inhibitors. Two NS3-4A protease inhibitors (telaprevir and boceprevir) have been recently approved for the treatment of hepatitis C in combination with standard of care (pegylated interferon plus ribavirin). The new therapy has significantly improved sustained virologic response (SVR); however, the adverse effects associated with this therapy are still the main concern. In addition to the emergence of viral resistance, other targets must be continually developed. One such underdeveloped target is the helicase portion of the HCV NS3 protein. This review article summarizes our current understanding of HCV treatment, particularly with those of NS3 inhibitors. Hindawi Publishing Corporation 2013 2013-10-27 /pmc/articles/PMC3825274/ /pubmed/24282816 http://dx.doi.org/10.1155/2013/467869 Text en Copyright © 2013 K. A. Salam and N. Akimitsu. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Salam, Kazi Abdus
Akimitsu, Nobuyoshi
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
title Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
title_full Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
title_fullStr Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
title_full_unstemmed Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
title_short Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
title_sort hepatitis c virus ns3 inhibitors: current and future perspectives
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825274/
https://www.ncbi.nlm.nih.gov/pubmed/24282816
http://dx.doi.org/10.1155/2013/467869
work_keys_str_mv AT salamkaziabdus hepatitiscvirusns3inhibitorscurrentandfutureperspectives
AT akimitsunobuyoshi hepatitiscvirusns3inhibitorscurrentandfutureperspectives